The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells

By K. Crozat, R. Guiton, V. Contreras, V. Feuillet, Charles-Antoine Dutertre, Erwan Ventre, Thien-Phong Vu Manh, T. Baranek, A. Storset, J. Marvel and 4 more. Journal of Experimental Medicine, 2010

656 citations recorded by the source corpus.

Human BDCA3+ dendritic cells (DCs) were suggested to be homologous to mouse CD8α+ DCs. We demonstrate that human BDCA3+ DCs are more efficient than their BDCA1+ counterparts or plasmacytoid DCs (pDCs) in cross-presenting antigen and activating CD8+ T cells, which is similar to mouse CD8α+ DCs as compared with CD11b+ DCs or pDCs, although with more moderate differences between human DC subsets. Yet, no specific marker was known to be shared between homologous DC subsets across species. We found that XC chemokine receptor 1 (XCR1) is specifically expressed and active in mouse CD8α+, human BDCA3+, and sheep CD26+ DCs and is conserved across species. The mRNA encoding the XCR1 ligand chemokine (C motif) ligand 1 (XCL1) is selectively expressed in natural killer (NK) and CD8+ T lymphocytes at steady-state and is enhanced upon activation. Moreover, the Xcl1 mRNA is selectively expressed at high levels in central memory compared with naive CD8+ T lymphocytes. Finally, XCR1−/− mice have decreased early CD8+ T cell responses to Listeria monocytogenes infection, which is associated with higher bacterial loads early in infection. Therefore, XCR1 constitutes the first conserved specific marker for cell subsets homologous to mouse CD8α+ DCs in higher vertebrates and promotes their ability to activate early CD8+ T cell defenses against an intracellular pathogenic bacteria.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/0bd40a7c7e8d316fa830e01420879ff8f9e392cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014, neutral): “Furthermore, when challenged with an intracellular bacterial pathogen Lysteria monocytogenes, Xcr12/2 mice have decreased early CD8+ T-cell responses associated with higher bacterial loads early in infection (Crozat et al., 2010).”
Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells (2012, methodology): “The production of CXCL10 by CD141hi DCs is interesting because XCL1 and CXCL10 potentially form a chemokine circuit between DCs bearing XCR1 and activated NK cells or Th1 cells (Dorner et al., 2009; Crozat et al., 2010a; Contreras et al., 2010).”
Development and function of dendritic cell subsets. (2014, positive): “Moreover, it led to the discovery of the human equivalent of CD8a and CD103 mouse DCs (Villadangos and Shortman, 2010) and the identification of the chemokine receptor XCR1 as a potential unifying marker of this DC subset in both human andmice (Bachem et al., 2010; Crozat et al., 2010; Dorner et al.”
Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “, 2013) and, when activated with poly I:C, efficiently cross-primeCD8Tcells (Bachemet al., 2010;Crozat et al., 2010; Haniffa et al., 2012; Jongbloed et al., 2010; Lauterbach et al., 2010; Mittag et al., 2011; Poulin et al., 2010).”
Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition (2016, neutral): “…CD103+ DCs, human CD141+ DCs express IRF8 and high levels of FLT3 and TLR3, and pIC activation of human CD141+ cells leads to the upregula- tion of PD-L1 (Bogunovic et al., 2011) and to their increased cross-priming of CD8+ T cells (Crozat et al., 2010; Jongbloed et al., 2010; Poulin et al., 2010).”
Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species (2016, background): “Although XCR1 identifies cDC1s in mouse (Crozat et al., 2010; Dorner et al., 2009) and is highly expressed on human and macaque cDC1s, as demonstrated with XCL1-mCherry vaccibodies, no commercial anti-human or anti-macaque XCR1 antibody is currently available.”
IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine Responses (2013, methodology): “…that a functionally-equivalent cross-presenting DC lineage is conserved in human peripheral tissues identifying the CD141hi DC subset with substantial cross-presenting capacities (Haniffa et al., 2012), similar to blood CD141+ DCs (Bachem et al., 2010; Crozat et al., 2010; Poulin et al., 2010).”
Human inflammatory dendritic cells induce Th17 cell differentiation. (2013, methodology): “First, we identified gene signatures for macrophages, BDCA1+ DCs, blood CD16+ or CD14+ monocytes, and in vitro-generated Mo-DCs using different sets of publicly available human expression data (Crozat et al., 2010a; Robbins et al., 2008).”
Cancer immunotherapy via dendritic cells (2012, positive): “CLEC9A-expressing CD141 DCs isolated from human lymph nodes were able to cross-present long peptides (requiring processing) of melanoma-tissue-derived antigen (MART-1) to T cell lines [46], whereas blood DCs can cross-present when activated via Toll-like receptor ligands [18, 19].”